Evaluating the Efficacy and Safety of BMS-986263 in | Clinical Research Studies Listing

Recruiting

99 years or below

All

75 participants needed

1 Location

Brief description of study

The purpose of this study is to test the effectiveness (how well the study drug works) and safety of BMS-986263 in participants with compensated cirrhosis from nonalcoholic steatohepatitis (NASH). The study drug BMS-986263, is investigational. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). Currently, there are no approved drugs for the treatment of NASH with compensated cirrhosis.

Detailed description of study

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research, Cirrhosis, Liver, Nonalcoholic Steatohepatitis, NASH
Age: 99 years or below
Gender: All

Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)

Updated on 04 Aug 2024. Study ID: 850532

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Evaluating the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)

Brief description of study

Detailed description of study

Eligibility of study

Find a site

Interested in the study